Histomorphometry is mainly used to quantitatively assess bone microarchitecture, formation, and remodeling by providing an insight on osseous cellular changes. Histomorphometry is of great value when monitoring different types of systemic bone diseases like osteoporosis, which costs Europe, Canada and the USA 5000 to 6000 billion USD per year without taking indirect losses like disability and loss of function into consideration[1], and osteomalacia.

Such a heavy burden on the healthcare system needs to be addressed; This is why at PharmaLegacy, we’ve put forward multiple histomorphometry models to accelerate the discovery of better treatments.